{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:26:56Z","timestamp":1761719216193},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose to increase the antibody titres after vaccination. Consequently, it is crucial to analyse the long-term humoral immune responses after COVID-19 primary vaccination and assess the immunogenicity and safety of booster doses in haemodialysis (HD) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients on maintenance haemodialysis who received the primary vaccine of CoronaVac (Sinovac) vaccine were administered with BNT162b2 (Pfizer-BioNTech) as the booster dose. The immunogenicity was assessed before (V1), one month (V2) and eight months (V3) after the primary vaccination, as well as one month after the booster dose (V4). Patients were followed up one month after the booster dose to assess the adverse events (AEs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The geometric mean titre (GMT) of anti-SARS-CoV-2 S-RBD IgG antibody at 8\u00a0months after the primary vaccination increased significantly to 5,296.63 (95%CI: 2,930.89\u20139,571.94) U\/mL (<jats:italic>p<\/jats:italic>\u2009=\u2009\u2009&lt;\u20090.0001) compared to before the primary vaccination. The GMT also increased significantly to 19,142.56 (95% CI: 13,489.63\u201327,227.01) U\/mL (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) 1\u00a0month after the booster vaccine. Meanwhile, the median inhibition rate of neutralizing antibodies (NAbs) at 8\u00a0months after the primary vaccine and 1\u00a0month after the booster dose were not significantly different (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.9999). The most common AEs after the booster dose included mild pain at the injection site (55.26%), mild fatigue (10.53%), and swelling at the injection site (10.53%). No serious AEs were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The majority of ESKD patients on haemodialysis mounted a good antibody response to the BNT162b2 booster vaccination with tolerable adverse events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03218-x","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T03:31:26Z","timestamp":1685417486000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Metalia","family":"Puspitasari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prenali D.","family":"Sattwika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auliana R. P.","family":"Hidayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wynne","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Wardhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umi S.","family":"Intansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nyoman","family":"Kertia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bambang","family":"Purwanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarir At","family":"Thobari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"3218_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.kint.2021.02.003","volume":"99","author":"A Francis","year":"2021","unstructured":"Francis A, Baigent C, Ikizler TA, Cockwell P, Jha V. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. Kidney Int. 2021;99:791\u20133.","journal-title":"Kidney Int"},{"key":"3218_CR2","unstructured":"UK Kidney Association. Covid-19 vaccination for adult patients with kidney disease: a position statement from the UK renal community. UK Kidney Association. 2020. https:\/\/ukkidney.org\/health-professionals\/covid-19\/ukka-resources\/covid-19-vaccination-adult-patients-kidney-disease. Accessed 2 Dec 2022."},{"key":"3218_CR3","doi-asserted-by":"crossref","unstructured":"Agur T, Zingerman B, Ben-Dor N, Alkeesh W, Steinmetz T, Rachamimov R, et al. Humoral response to the third dose of BNT162b2 COVID-19 vaccine among hemodialysis patients. Nephron. 2022;:1\u20138.","DOI":"10.1159\/000525519"},{"key":"3218_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281160","volume":"18","author":"M Puspitasari","year":"2023","unstructured":"Puspitasari M, Sattwika PD, Rahari DS, Wijaya W, Hidayat ARP, Kertia N, et al. Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: a systematic review and meta-analysis. PLoS One. 2023;18: e0281160.","journal-title":"PLoS ONE"},{"key":"3218_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5005\/japi-11001-0110","volume":"70","author":"S Mohith","year":"2022","unstructured":"Mohith S, Chandrashekhar H. Breakthrough covid 19 infections after 2 doses of covid 19 vaccination and comparing severity between hospitalized and non hospitalized in tertiary care hospital. J Assoc Physicians India. 2022;70:11\u20132.","journal-title":"J Assoc Physicians India"},{"key":"3218_CR6","doi-asserted-by":"crossref","unstructured":"Duarte LF, G\u00e1lvez NMS, Iturriaga C, Melo-Gonz\u00e1lez F, Soto JA, Schultz BM, et al. Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine. Front Immunol. 2021;12 September:1\u201313.","DOI":"10.3389\/fimmu.2021.742914"},{"key":"3218_CR7","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","volume":"384","author":"E Hacisuleyman","year":"2021","unstructured":"Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384:2212\u20138.","journal-title":"N Engl J Med"},{"key":"3218_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/j.ajkd.2021.09.002","volume":"79","author":"N Nacasch","year":"2022","unstructured":"Nacasch N, Erez D, Lishner M, Benchetrit S, Rozenberg I, Sarel E, et al. Long-term antibody response to the BNT162b2 vaccine among maintenance hemodialysis patients. Am J Kidney Dis. 2022;79:137\u20139.","journal-title":"Am J Kidney Dis"},{"key":"3218_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ekir.2022.02.007","volume":"7","author":"AS De Vriese","year":"2022","unstructured":"De Vriese AS, Van Praet J, Reynders M, Heylen L, Viaene L, Caluw\u00e9 R, et al. Longevity and clinical effectiveness of the humoral and cellular responses to SARS-CoV-2 Vaccination in Hemodialysis Patients. Kidney Int Reports. 2022;7:1103\u20137.","journal-title":"Kidney Int Reports"},{"key":"3218_CR10","first-page":"1","volume":"17","author":"J Stumpf","year":"2022","unstructured":"Stumpf J, Schw\u00f6bel J, Lindner T, Anders L, Siepmann T, Karger C, et al. Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: six months data from the observational Dia-Vacc study. Lancet Reg Heal - Eur. 2022;17:1\u201318.","journal-title":"Lancet Reg Heal - Eur"},{"key":"3218_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399:521\u20139.","journal-title":"Lancet"},{"key":"3218_CR12","doi-asserted-by":"crossref","unstructured":"Shashar M, Nacasch N, Grupper A, Benchetrit S, Halperin T, Erez D, et al. Humoral response to Pfizer BNT162b2 vaccine booster in maintenance hemodialysis patients. Am J Nephrol. 2022;:1\u20138.","DOI":"10.1159\/000521676"},{"key":"3218_CR13","unstructured":"Food and Drug Administration. Roche diagnostics elecsys Anti-SARS-CoV-2 - IFU. 2020. https:\/\/www.fda.gov\/media\/137605. Accessed 3 Dec 2022."},{"key":"3218_CR14","unstructured":"Genscript. GenScript cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit. 2020;:0\u201318."},{"key":"3218_CR15","unstructured":"Food and Drug Administration of America. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine Clinical Trials | FDA. 2007. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical. Accessed 14 Nov 2022."},{"key":"3218_CR16","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.2021.19996","volume":"326","author":"D Zhong","year":"2021","unstructured":"Zhong D, Xiao S, Debes AK, Egbert ER, Caturegli P, Colantuoni E, et al. Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in Individuals with or without prior infection. JAMA. 2021;326:2524\u20136.","journal-title":"JAMA"},{"key":"3218_CR17","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/ckj\/sfac148","volume":"15","author":"L Fu\u00ebssl","year":"2022","unstructured":"Fu\u00ebssl L, Lau T, Rau S, Regenauer R, Paal M, Hasmann S, et al. Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection. Clin Kidney J. 2022;15:1633\u20135.","journal-title":"Clin Kidney J"},{"key":"3218_CR18","doi-asserted-by":"crossref","unstructured":"Peiyao R, Mengjie Y, Xiaogang S, Wenfang H, Danna Z, Yuqun Z, et al. Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: a systematic review and meta-analysis. Front Public Heal. 2022;10:951096.","DOI":"10.3389\/fpubh.2022.951096"},{"key":"3218_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X","volume":"397","author":"M Prendecki","year":"2021","unstructured":"Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397:1178\u201381.","journal-title":"Lancet"},{"key":"3218_CR20","doi-asserted-by":"crossref","unstructured":"Ranzani OT, Hitchings MDT, Dorion M, D\u2019Agostini TL, De Paula RC, De Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021;374:n2015.","DOI":"10.1136\/bmj.n2015"},{"key":"3218_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35\u201345.","journal-title":"JAMA"},{"key":"3218_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/vaccines10040585","volume":"10","author":"S Patyna","year":"2022","unstructured":"Patyna S, Eckes T, Koch BF, Sudowe S, Oftring A, Kohmer N, et al. Impact of moderna mRNA-1273 booster vaccine on fully vaccinated high-risk chronic dialysis patients after loss of humoral response. Vaccines. 2022;10:585.","journal-title":"Vaccines"},{"key":"3218_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-07574-w","volume":"12","author":"J Bruminhent","year":"2022","unstructured":"Bruminhent J, Setthaudom C, Kitpermkiat R, Kiertiburanakul S, Malathum K, Assanatham M, et al. Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients. Sci Rep. 2022;12:1\u20139.","journal-title":"Sci Rep"},{"key":"3218_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.04.011","volume":"84","author":"CY Cheng","year":"2022","unstructured":"Cheng CY, Hsiao SH, Fang TC, Lin YC, Wang JCC, Hung CS, et al. SARS-CoV2 antibody response after a third dose of heterologous ChAdOx1 nCoV-19 and Moderna vaccine in chronic dialysis patients. J Infect. 2022;84: e98.","journal-title":"J Infect"},{"key":"3218_CR25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/ckj\/sfac169","volume":"15","author":"B Quiroga","year":"2022","unstructured":"Quiroga B, Soler MJ, Ortiz A, JaravacaMantec\u00f3n CJ, Nava P\u00e9rez N, Serra Mart\u00edn M, et al. Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study. Clin Kidney J. 2022;15:1856\u201364.","journal-title":"Clin Kidney J"},{"key":"3218_CR26","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2215\/CJN.03500321","volume":"16","author":"A Grupper","year":"2021","unstructured":"Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2021;16:1037\u201342.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3218_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.ajkd.2021.08.005","volume":"79","author":"I Bensouna","year":"2022","unstructured":"Bensouna I, Caudwell V, Kubab S, Acquaviva S, Pardon A, Vittoz N, et al. SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am J Kidney Dis. 2022;79:185-192.e1.","journal-title":"Am J Kidney Dis"},{"key":"3218_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40620-022-01371-4","volume":"36","author":"H Karakizlis","year":"2023","unstructured":"Karakizlis H, Agarwal V, Aly M, Strecker K, Csala B, Esso I, et al. Humoral and cellular immune responses to the mRNA-1273 SARS-CoV-2 vaccine booster in patients on maintenance dialysis. J Nephrol. 2023;36:183\u20136.","journal-title":"J Nephrol"},{"issue":"558","key":"3218_CR29","first-page":"13","volume":"2021","author":"K Nayak","year":"2020","unstructured":"Nayak K, Gottimukkala K, Kumar S, Reddy ES, Edara VV, Kauffman R, et al. Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India. Virology. 2020;2021(558):13\u201321.","journal-title":"Virology"},{"key":"3218_CR30","doi-asserted-by":"crossref","unstructured":"Weber MC, Risch M, Thiel SL, Grossmann K, Nigg S, Wohlwend N, et al. Characteristics of three different chemiluminescence assays for testing for SARS-CoV-2 antibodies. Dis Markers. 2021;2021 Cmv.","DOI":"10.1155\/2021\/8810196"},{"key":"3218_CR31","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","volume":"386","author":"ED Moreira","year":"2022","unstructured":"Moreira ED, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and Efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386:1910\u201321.","journal-title":"N Engl J Med"},{"key":"3218_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457\u201362.","journal-title":"Nature"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03218-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03218-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03218-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T03:32:07Z","timestamp":1685417527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03218-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3218"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03218-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects and\/or their legal guardian(s). All methods were carried out in accordance with relevant guidelines and regulations i.e., Declaration of Helsinki and Good Clinical Practice. All study protocols were approved by The Medical and Health Research Ethics Committee of the Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia (No. KE\/FK\/1005\/EC\/2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}